These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 1175127)
21. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma. Hollinshead A; Arlen M; Yonemoto R; Cohen M; Tanner K; Kundin WD; Scherrer J Cancer; 1982 Apr; 49(7):1387-404. PubMed ID: 7059953 [TBL] [Abstract][Full Text] [Related]
22. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response. Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886 [No Abstract] [Full Text] [Related]
23. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108 [TBL] [Abstract][Full Text] [Related]
24. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy]. Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404 [TBL] [Abstract][Full Text] [Related]
25. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens. Roth JA; Grimm EA; Morton DL Cancer Res; 1976 Sep; 36(9 pt.1):3001-10. PubMed ID: 975069 [TBL] [Abstract][Full Text] [Related]
26. Immunocompetence, immunodeficiency and prognosis in cancer. Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324 [TBL] [Abstract][Full Text] [Related]
27. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166 [TBL] [Abstract][Full Text] [Related]
28. Role of the regional lymph node in neoplasia: cellular mediated reactivity in vitro by autologous regional or distant lymph nodes or peripheral blood lymphocytes of dogs with spontaneous neoplasms. Fidler IJ; McWilliams RW; Bech-Nielsen S; Budmen MB Immunol Commun; 1975; 4(4):325-35. PubMed ID: 1184114 [TBL] [Abstract][Full Text] [Related]
29. [Activity of lymphocytes from patients with malignant melanoma in a culture with phytohemagglutinin]. Sergeev SI; Gorodilova VV; Sokolova II; Repina FF; Babakova SV Vopr Onkol; 1976; 22(7):6-10. PubMed ID: 997408 [TBL] [Abstract][Full Text] [Related]
30. [Nonspecific cell-mediated immunity in gastric cancer patients - with special reference to immuno-reactivity of the regional lymph node and preoperative immunotherapy]. Takeshita M Nihon Geka Gakkai Zasshi; 1983 Aug; 84(8):679-91. PubMed ID: 6610095 [TBL] [Abstract][Full Text] [Related]
31. Effect of epidermal Langerhans cells from melanoma patients on lymphoproliferative responses. Stene MA; Holthoj-Asnong C; Cochran AJ Melanoma Res; 1992 May; 2(1):57-62. PubMed ID: 1643425 [TBL] [Abstract][Full Text] [Related]
32. Some aspects of cell-mediated hypersensitivity in patients with melanoma. Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028 [TBL] [Abstract][Full Text] [Related]
33. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma. Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203 [TBL] [Abstract][Full Text] [Related]
34. Human malignant melanoma antigenic properties of phenol water extracts. Suter L; Tilkorn H; Kövary PM Arch Dermatol Res; 1979 Feb; 264(1):37-47. PubMed ID: 443860 [TBL] [Abstract][Full Text] [Related]
35. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy. Golub SH; Forsythe AB; Morton DL Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880 [TBL] [Abstract][Full Text] [Related]
36. Phytohemagglutinin skin test: diagnostic value for showing immunodeficiency in patients with cancer. Sone S; Taoka S; Yata K; Tsubura E; Nakano Y Gan; 1975 Dec; 66(6):641-8. PubMed ID: 1225717 [TBL] [Abstract][Full Text] [Related]
37. In vitro assessment of immunocompetence in patients with malignant melanoma. Golub SH; Rangel DM; Morton DL Int J Cancer; 1977 Dec; 20(6):873-80. PubMed ID: 591127 [TBL] [Abstract][Full Text] [Related]
38. Immunologic study on nasopharyngeal carcinoma patients: correlation of in vivo and in vitro reactivity to phytohemagglutinin. Hsu MM; Lo P Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1983 Feb; 16(1):20-32. PubMed ID: 6851721 [TBL] [Abstract][Full Text] [Related]
39. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742 [TBL] [Abstract][Full Text] [Related]
40. Evidence for tumor-specific immunity in human malignant melanoma. Nagel GA; Piessens WF; Stilmant MM; Lejeune F Eur J Cancer (1965); 1971 Feb; 7(1):41-7. PubMed ID: 5576728 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]